KyungDong Pharm Co., Ltd. will release the “Telcadin Series” of ARB blood pressure lowering drugs containing Telmisartan on August 1, 2025.

“Telcadin Series” consists of single drug ‘Telcadin Tablets 20mg, 40mg, 80mg’ with Telmisartan as the main ingredient.

‘Telcardipine Tablets 40/5mg, 40/10mg, and 80/5mg,’ a CCB-based amlodipine ingredient complex, will be released in a total of 6 products with 3 strengths.

Telcadin tablets are differentiated in that they diversify patients' treatment options by launching a low-dose 20mg product.

In addition, all six products in the Telcardin series improved their usability and were released in bottled packaging, thereby improving patient compliance.

KyungDong Pharm Co., Ltd. has launched the “Telcadin Series” following the ARB hypertension treatment “Valtrep Series,” “Cansata Series,” and “Olodipine Series.”

In the future, it is expected to further solidify its position as a company specializing in hypertension treatment.

 

※ Product information

『 Launch of ARB hypertension treatment drugs ‘Telcadin Tablets’ and ‘Telcardipine Tablets’, which are packaged in bottles to increase convenience of administration』

『 Launch of ARB hypertension treatment drugs ‘Telcadin Tablets’ and ‘Telcardipine Tablets’, which are packaged in bottles to increase convenience of administration』